Abstract:Background: There are limited data on outcomes of older patients with chronic diseases. Skeletal muscle loss of aging (primary sarcopenia) has been extensively studied but the impact of secondary sarcopenia of chronic disease is not as well evaluated. Older patients with chronic diseases have both primary and secondary sarcopenia that we term compound sarcopenia. We evaluated the clinical impact of compound sarcopenia in hospitalized patients with cirrhosis given the increasing number of patients and high prevalence of sarcopenia in these patients. Design: The Nationwide Inpatients Sample (NIS) database (years 2010–2014) was analyzed to study older patients with cirrhosis. Since there is no universal hospital diagnosis code for “muscle loss”, we used a comprehensive array of codes for “muscle loss phenotype” in the international classification of diseases-9 (ICD-9). A randomly selected 2% sample of hospitalized general medical population (GMP) and inpatients with cirrhosis were stratified into 3 age groups based on age-related changes in muscle mass. In-hospital mortality, length of stay (LoS), cost of hospitalization (CoH), comorbidities and discharge disposition were analyzed. Results. Of 517,605 hospitalizations for GMP and 106,835 hospitalizations for treatment of cirrhosis or a cirrhosis-related complication, 207,266 (40.4%) GMP and 29,018 (27.7%) patients with cirrhosis were >65 years old, respectively. Muscle loss phenotype in both GMP and inpatients with cirrhosis 51–65 years old and >65 years old was significantly (p 65 years old with cirrhosis and muscle loss phenotype had higher mortality (adjusted OR: 1.06, 95% CI [1.04, 1.08] and CoH (adjusted odds ratio (OR): 1.10, 95% confidence interval (CI) [1.04, 1.08])) when compared to >65 years old GMP with muscle loss phenotype. Muscle loss in younger patients with cirrhosis (≤50 years old) was associated with worse outcomes compared to GMP >65 years old. Non-home discharges (nursing, skilled, long-term care) were more frequent with increasing age to a greater extent in patients with cirrhosis with muscle loss phenotype for each age stratum. Conclusion: Muscle loss is more frequent in older patients with cirrhosis than younger patients with cirrhosis and older GMP. Younger patients with cirrhosis had clinical outcomes similar to those of older GMP, suggesting an accelerated senescence in cirrhosis. Compound sarcopenia in older patients with cirrhosis is associated with higher inpatient mortality, increased LoS, and CoH compared to GMP with sarcopenia.

Sarkopenie erhöht Fibroserisiko bei NAFLD

Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice

Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease

Erhöhtes Infektionsrisiko bei nichtalkoholischer Fettlebererkrankung (NAFLD)?

Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease

Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease.

Globale Prävalenz von Typ-2-Diabetes und NAFLD

Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis

A short history of sarcopenia and frailty and their impact on advanced chronic liver disease

Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis

THERE IS NO CORRELATION BETWEEN STAGES OF NAFLD ASSESSED BY LIVER BIOPSY AND THE DIAGNOSTIC CRITERIA FOR SARCOPENIA IN ACTIVE POPULATIONS: A CROSS-SECTIONAL STUDY

ABDOMEN BECKEN – Sarkopenie steigert perioperative Komplikationsrate

Compound Sarcopenia in Hospitalized Patients with Cirrhosis Worsens Outcomes with Increasing Age

The presence of sarcopenia at baseline seems to affect the fibrosis amelioration in patients with metabolic dysfunction associated steatotic liver disease

Einfacher Risiko-Score zur Beurteilung einer Leberfibrose bei Verwandten

Strong association between sarcopenic obesity and non-alcoholic fatty liver disease: An observational study with ISarcoPRM algorithm

Emerging drugs for the treatment of sarcopenia in cirrhosis of the liver

Fast Food begünstigt Fettleber

Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis